Amova Asset Management Americas Inc. Has $62.86 Million Stock Holdings in 10x Genomics $TXG

Amova Asset Management Americas Inc. decreased its stake in 10x Genomics (NASDAQ:TXG) by 10.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,376,883 shares of the company’s stock after selling 632,770 shares during the quarter. Amova Asset Management Americas Inc. owned 4.32% of 10x Genomics worth $62,856,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of TXG. Allworth Financial LP boosted its holdings in shares of 10x Genomics by 150.4% in the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after buying an additional 1,364 shares during the period. True Wealth Design LLC boosted its position in shares of 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after buying an additional 3,369 shares during the period. Abich Financial Wealth Management LLC purchased a new position in shares of 10x Genomics during the third quarter valued at $56,000. EverSource Wealth Advisors LLC raised its position in 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after buying an additional 5,025 shares during the period. Finally, Focus Partners Wealth purchased a new stake in 10x Genomics in the 1st quarter worth about $92,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TXG. Barclays upped their target price on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft set a $17.00 target price on shares of 10x Genomics and gave the company a “hold” rating in a research note on Friday, February 13th. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Stifel Nicolaus boosted their target price on 10x Genomics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday. Finally, Leerink Partners reduced their price target on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a report on Tuesday, January 27th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, 10x Genomics presently has an average rating of “Hold” and an average target price of $18.46.

10x Genomics Price Performance

NASDAQ TXG opened at $22.37 on Thursday. The company’s fifty day moving average is $19.69 and its two-hundred day moving average is $16.27. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $23.56. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -63.91 and a beta of 2.20.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The business had revenue of $166.03 million during the quarter, compared to analyst estimates of $160.35 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. As a group, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other 10x Genomics news, CFO Adam Taich sold 8,968 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total value of $166,625.44. Following the sale, the chief financial officer owned 288,417 shares of the company’s stock, valued at $5,358,787.86. The trade was a 3.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Serge Saxonov sold 9,632 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $178,962.56. Following the completion of the transaction, the chief executive officer owned 1,061,924 shares of the company’s stock, valued at approximately $19,730,547.92. This represents a 0.90% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 26,426 shares of company stock worth $490,995. 9.39% of the stock is currently owned by company insiders.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.